Literature DB >> 24122005

Elevated [Ca2+]i levels occur with decreased calpain activity in aged fibroblasts and their reversal by energy-rich compounds: new paradigm for Alzheimer's disease prevention.

Huey T Nguyen1, Darrell R Sawmiller, Olga Markov, Ming Chen.   

Abstract

Elevated intracellular Ca2+ levels in the aging brain are widely thought to hyperactivate Ca2+ signaling and Ca2+-dependent enzymes, leading to neuronal death through an excitatory mechanism in Alzheimer's disease (AD). This "Ca2+ overload" hypothesis has been questioned by our theoretical analyses. To better understand the relationship between the "level" and functionality of Ca2+ in aging, in this study we simultaneously measured intracellular Ca2+ transients and calpain activity in cultured human fibroblasts. We found that Ca2+ transitions elicited by bradykinin were indeed overstayed or elevated in levels in old cells but, remarkably, calpain activity was decreased compared to young cells. Also, treating young cells with the energy inhibitor rotenone or with H2O2 recapitulated the Ca2+ overstay and calpain inactivation found in old cells. More importantly, treating old cells with high-energy compounds such as phosphoenol pyruvate or phosphocreatine, which boosted cellular ATP content, reduced the Ca2+ overstay and re-activated calpain. Moreover, Ca2+ levels and calpain activity were dramatically raised in the dying cells killed by detergent. Finally, Ca2+ oscillations induced by low dose of bradykinin in old cells exhibited lower spike frequency, but higher overall levels. Collectively, these results suggest that (a) Ca2+ overload in old cells arises from an inefficient Ca2+ handling system compromised by age-related energy depletion and oxidative stress; and (b) despite elevated levels, the functionality of Ca2+ signaling has diminished in old cells. Thus, the study reinforces the concept that tonic promotion of bioenergetics and Ca2+ signaling function is a reasonable and new paradigm to protect the aging brain cells to prevent AD.

Entities:  

Keywords:  Alzheimer's disease; calcium; calpain; energy

Mesh:

Substances:

Year:  2013        PMID: 24122005     DOI: 10.3233/JAD-131001

Source DB:  PubMed          Journal:  J Alzheimers Dis        ISSN: 1387-2877            Impact factor:   4.472


  7 in total

1.  Redox and mTOR-dependent regulation of plasma lamellar calcium influx controls the senescence-associated secretory phenotype.

Authors:  Akshaya Chandrasekaran; May Y Lee; Xuexin Zhang; Shaheen Hasan; Habben Desta; Scott A Tenenbaum; J Andrés Melendez
Journal:  Exp Biol Med (Maywood)       Date:  2020-07-19

2.  Memantine, a Low-Affinity NMDA Receptor Antagonist, Protects against Methylmercury-Induced Cytotoxicity of Rat Primary Cultured Cortical Neurons, Involvement of Ca2+ Dyshomeostasis Antagonism, and Indirect Antioxidation Effects.

Authors:  Wei Liu; Zhaofa Xu; Tianyao Yang; Bin Xu; Yu Deng; Shu Feng
Journal:  Mol Neurobiol       Date:  2016-08-18       Impact factor: 5.590

3.  Prevalence of and Factors Associated with Dural Thickness in Patients with Mild Cognitive Impairment and Alzheimer's Disease.

Authors:  Adnan I Qureshi; Iryna Lobanova; Naseeb Ullah; Amna Sohail; Taqi A Zafar; Adil M Malik; Mushtaq H Qureshi
Journal:  J Vasc Interv Neurol       Date:  2015-07

Review 4.  The Maze of APP Processing in Alzheimer's Disease: Where Did We Go Wrong in Reasoning?

Authors:  Ming Chen
Journal:  Front Cell Neurosci       Date:  2015-05-28       Impact factor: 5.505

5.  Our "energy-Ca(2+) signaling deficits" hypothesis and its explanatory potential for key features of Alzheimer's disease.

Authors:  Ming Chen; Huey T Nguyen
Journal:  Front Aging Neurosci       Date:  2014-12-03       Impact factor: 5.750

Review 6.  Nutraceuticals against Neurodegeneration: A Mechanistic Insight.

Authors:  Vivekkumar P Dadhania; Priyanka P Trivedi; Ajit Vikram; Durga Nand Tripathi
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363

7.  Inhibition of GPR35 Preserves Mitochondrial Function After Myocardial Infarction by Targeting Calpain 1/2.

Authors:  Ken Chen; Lei He; Yong Li; Xiuchuan Li; Chenming Qiu; Haifeng Pei; Dachun Yang
Journal:  J Cardiovasc Pharmacol       Date:  2020-06       Impact factor: 3.271

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.